Chardan initiated coverage of Kalaris Therapeutics (KLRS) with a Buy rating and $19 price target The firm cites the commercial potential of the company’s lead candidate TH103 in wet age-related macular degeneration for the Buy rating. Kalaris has further opportunities to expand into diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS:
- Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
- Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
- Kalaris Therapeutics price target raised to $26 from $20 at Citizens
- Kalaris Therapeutics announces $50M private placement
- Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27